TY  - GEN
AU  - Miranda,M B
AU  - Lauseker,M
AU  - Kraus,M-P
AU  - Proetel,U
AU  - Hanfstein,B
AU  - Fabarius,A
AU  - Baerlocher,G M
AU  - Heim,D
AU  - Hossfeld,D K
AU  - Kolb,H-J
AU  - Krause,S W
AU  - Nerl,C
AU  - Brümmendorf,T H
AU  - Verbeek,W
AU  - Fauser,A A
AU  - Prümmer,O
AU  - Neben,K
AU  - Hess,U
AU  - Mahlberg,R
AU  - Plöger,C
AU  - Flasshove,M
AU  - Rendenbach,B
AU  - Hofmann,W-K
AU  - Müller,M C
AU  - Pfirrmann,M
AU  - Hochhaus,A
AU  - Hasford,J
AU  - Hehlmann,R
AU  - Saußele,S
TI  - Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV
SN  - 1476-5551
PY  - 2017///0829
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Colorectal Neoplasms
KW  - chemically induced
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Imatinib Mesylate
KW  - adverse effects
KW  - Incidence
KW  - Interferon-alpha
KW  - therapeutic use
KW  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive
KW  - complications
KW  - Lymphoma, Non-Hodgkin
KW  - Male
KW  - Middle Aged
KW  - Neoplasms, Second Primary
KW  - Protein Kinase Inhibitors
KW  - Sex Factors
N1  - Publication Type: Journal Article; Observational Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1038/leu.2016.20
ER  -